GD2


Also found in: Wikipedia.
AcronymDefinition
GD2Great Depression 2
GD2Great Divide 2 (game)
References in periodicals archive ?
Additional investigations on the territory of the placement of grounding devices GD1, GD2 and GD3 are to remove the gradient curves in an easy direction to connect the variants of Fig.
A CTC immunocapture was developed utilizing IgM human mAb against 3 melanoma-related gangliosides [GM3 (13), GM2 (14), and GD2 (15)] coupled to immunomagnetic beads.
Population name Sample name Host Species Dysmicoccus brevipes Jinghong YN1 Ananas comosus Jinggu YN2 Ananas comosus Longzhou GX1 Ananas comosus Nanning GX2 Ananas comosus Pubei GX3 Ananas comosus Xuwen QJ1 Ananas comosus Leizhou GD1 Ananas comosus GD2 Ananas comosus GD3 Ananas comosus Wanning WN1 Ananas comosus Qionghai QH1 Ananas comosus HN1 Ananas comosus Zhangzhou FJ1 Ananas comosus FJ2 Ananas comosus Hawaii HI1 Ananas comosus Dysmicoccus neobrevipes D.
Oviducts were collected on GD2 (48 hr after hCG), and embryos were removed.
Libreria GD2 de PHP activada, y en version igual o posterior a la 2.
La enolasa especifica de neurona y el GD2 sericos son especificos pero no tan sensibles y no siempre estan disponibles.
Analysis for specific ganglioside fractions, for example, GD2, GD3, 0-Ac-GD3, or GM2, is nevertheless valuable in the context of immunotherapy with antiganglioside antibodies or with ganglioside-containing antimelanoma vaccine.
For the MT-GD2, Trojan GD2 and the TLS-GD2 interlock switches a sliding bolt actuator is available.
The heavy duty Sipha GD2 is the latest addition to Guardmaster's Sipha family of magnetically coded safety switches, and the makers reckon they offer performance better than or equal to most mechanical safety interlocks,
Using the augmentation axiom GD2 of GD-constraints, we have Laboratory [right arrow] {Project} (Staff, Laboratory) [right arrow] (project}.
ISQETTE is a monoclonal antibody that specifically targets the GD2 antigen expressed on the surface of neuroblastoma cells and thereby initiates a selective immunological attack against these tumor cells.
The registered numbers of clinical trials increase annually, and a range of tumor antigens, including CEA, mesothelin, HER2, and GD2, are being targeted for various solid tumors.